Sotera Health earnings beat by $0.02, revenue topped estimates
Sotera Health (SHC) reported Q3 EPS of $0.29, beating estimates by $0.02, with revenue at $324.89M, topping expectations. The company provided FY 2026 guidance, with EPS and revenue estimates slightly below consensus. SHC's stock is down 5.94% over 3 months but up 7.97% year-over-year.
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the beat and the FY26 guidance ranges, and reassess whether recent EPS revision momentum is improving or deteriorating.
Market read
Q3 beat plus FY26 guidance near consensus creates a tradable setup, but the lack of a large guidance surprise suggests more incremental than transformative repricing.
What to watch
The article notes 2 positive and 4 negative EPS revisions over 90 days, which could temper enthusiasm even after the quarter beat.
Background
This is Sotera Health’s Q3 earnings report with explicit FY26 EPS and revenue guidance ranges versus analyst consensus.
Ticker impact
Sotera Health reported Q3 EPS of $0.29, beating $0.27 consensus, and revenue of $324.89M versus $319.84M, plus FY26 EPS and revenue guidance.
Likely modest support as the market digests the beat and guidance, with follow-through dependent on how investors interpret the mix of EPS revisions.
The article provides concrete Q3 results and FY26 guidance ranges versus consensus, but does not include margins, backlog, or a major surprise that would strongly reprice the stock.
Market effects
Adds incremental signal on managed care and healthcare services demand and cost discipline, but no sector-wide read-through is provided.
No specific regional linkage beyond US healthcare equities.
Primarily US-listed company earnings, with limited global spillover.
Counterpoint
The guidance is close to consensus, so the stock reaction may fade if investors were already positioned for a beat and focus shifts to forward margin or utilization trends not discussed here.
Key entities
- companySotera Health
NASDAQ-listed healthcare services company reporting Q3 results and FY26 guidance.



